Daratumumab, isatuximab (CD38 drugs)

But IGG did go down in Fluge et al.

Someone who took the time to look at the paper (unlike me) has pointed out the baseline IGG was low due to pretreatment.

I wondered that. So things do not necessarily go as pear-shaped as it seemed.
But resistant plasma cells are perhaps most likely to be the long lived bone marrow ones. So Fluge and Mella may just have killed the easy short lived ones that rituximab depletes. Ritux does tend to produce falls in IgM and IgA but not much in IgG.
 
Back
Top Bottom